Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Inhibition of the Caveolin-1 Pathway Promotes Apoptosis and Overcomes Pan-Tyrosine Kinase Inhibitor Resistance in Hepatocellular Carcinoma

July 25, 2025

[Cell Death & Disease] Researchers used multiple tyrosine kinase inhibitors (TKI)-resistant HCC cell lines to identify caveolin-1 (CAV1) as a key driver of therapeutic resistance. CAV1 downregulation induces apoptosis, inhibits metastasis, and restores TKI sensitivity in both inherent and acquired TKI-resistant HCC cells.

Differential Expression Pattern of CC Chemokine Receptor 7 Guides Precision Treatment of Hepatocellular Carcinoma

July 25, 2025

[Signal Transduction and Targeted Therapy] Investigators highlight the opposing effects of tumor cell-derived versus stromal cell-derived CCR7 expression and guides the precision treatment for HCC.

AusperBio Receives China CDE Clearance to Advance AHB-137 into Phase III Clinical Trial for Chronic Hepatitis B

July 25, 2025

[AusperBio Therapeutics, Inc. (BioSpace)] AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio) announced that the China Center for Drug Evaluation has approved the initiation of a Phase III clinical trial for its lead candidate, AHB-137.

FDA Approves Y-90 Resin Microspheres for Patients With Unresectable HCC

July 25, 2025

[Oncology Nurse Advisor] The US FDA has approved the use of Sirtex Medical’s Y-90 resin microspheres to treat unresectable HCC.

Survival in Patients with Unresectable Hepatocellular Carcinoma: TCC Cocktail Plus TACE Vs TACE Alone Prospective Randomized Clinical Trial

July 25, 2025

[Journal of Translational Medicine] For patients with unresectable HCC, transarterial chemoembolization (TACE) combined with thalidomide, carmofur, and compound mylabris (TCC) cocktail was well tolerated and significantly improved clinical outcomes.

A Novel Chronic Hepatitis B Mouse Model with Immune Activation and Liver Fibrosis

July 25, 2025

[Microbiology Spectrum] Researchers introduced a novel hepatitis B virus (HBV) mouse model via injections of porcine serum in combination with hydrodynamic injection of pAAV-HBV1.2 plasmid. They validated the characteristics of this model by treating the model with entecavir, an HBV replication blocker.

From Preneoplastic Lesion to Heterogenous Tumor: Recent Insights into Hepatoblastoma Biology and Therapeutic Opportunities

July 25, 2025

[Molecular Cancer] The authors review recent findings in pediatric hepatoblastoma cells, tumor-associated cell types, and genetic dependencies that will serve to advance hepatoblastoma therapy.

Intercellular Communication between Hepatic Stellate Cells and Myofibroblasts Mediated by Osteopontin and FGF18 Promotes Liver Fibrosis

July 25, 2025

[iScience] Investigators showed that fibroblast growth factor 18 (FGF18) efficiently induced osteopontin expression in culture-activated αSMA⁺ hepatic stellace cells (HSCs), but not in freshly prepared quiescent HSCs.

Somatic Mutations in TBX3 Promote Hepatic Clonal Expansion by Accelerating VLDL Secretion

July 23, 2025

[Journal of Clinical Investigation] The authors detected TBX3 somatic mutations in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Modulation of Metabolic, Inflammatory, and Fibrotic Pathways by Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

July 23, 2025

[Nature Medicine] Scientists show that, in two preclinical metabolic dysfunction-associated steatohepatitis (MASH) models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways.

Mevalonate Pathway Promotes Liver Cancer by Suppressing Ferroptosis through CoQ10 Production and Selenocysteine-tRNA Modification

July 18, 2025

[Journal of Hepatology] Researchers discovered that targeting the mevalonate pathway promotes ferroptosis in HCC by impairing CoQ10 synthesis and selenoprotein translation.

Altimmune Announces Initiation of RESTORE Phase II Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

July 11, 2025

[Altimmune, Inc. ] Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase II trial evaluating the efficacy and safety of pemvidutide in subjects with ALD.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!